Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy

  • Christof SchaeferEmail author
  • Reinhard Meister
  • Corinna Weber-Schoendorfer
Original Article



Apart from thalidomide, retinoids like isotretinoin are the strongest teratogens in humans known today. The overall risk of birth defects is estimated as up to 30% after exposure during embryogenesis. In spite of well established pregnancy prevention programs, pregnancies still occur during isotretinoin therapy in many countries including Germany. A detailed investigation of the incidence and outcome of these pregnancies would fill an important gap.


The Berlin Institute for Clinical Teratology documents prospectively the course of drug-exposed pregnancies when contacted for individual drug risk assessment. Datasets of isotretinoin exposed pregnancies recorded between 1993 and 2008 were evaluated as to the outcome of pregnancy.


A total of 108 pregnancies exposed to systemic isotretinoin (median dosage 20 mg/day) during the contraindicated period were registered. 76% (69/91) of the pregnancies with known outcome were electively terminated—mainly for fear of medication risk. No terminations due to abnormal prenatal ultrasound findings were reported. Spontaneous abortions occurred in five pregnancies. Of 18 live births including 1 pair of twins 1 major birth defect (small ventricular septal defect) was observed. None of the infants showed symptoms of retinoid embryopathy. 70% (48/69) of the patients with data on contraception did not use any method, in 30% contraception failed. There was no evidence that poor maternal education was a major cause for the omission of contraception documented in 48 women.


Inadvertent isotretinoin exposure during the first 2 weeks post conception does not necessarily require discussion of termination of pregnancy, as the risk of major birth defects appears to be much lower than it becomes beyond this period. Nevertheless, additional efforts are required to improve the effectiveness of contraception while on isotretinoin treatment considering psycho-social aspects such as improved self-confidence, unexpected new partnership and sexual activity and incorrect perception of infertility.


Isotretinoin Retinoids Pregnancy Acne Contraception Fetal outcome Pregnancy outcome Teratogenicity 



The authors thank Dr. Dorothy Rosenberg, Maine, USA, for critical reading of the manuscript. The study was performed with financial support from the Bundesinstitut für Arzneimittel und Medizinprodukte (German Federal Institute for Drugs and Medical Devices).

Conflict of interest statement



  1. 1.
    Abroms L, Maibach E, Lyon-Daniel K, Feldman SR (2006) What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 3:e483. doi: 10.1371/journal.pmed.0030483 CrossRefPubMedGoogle Scholar
  2. 2.
    Adams J (2004) The adverse effect profile of neurobehavioral teratogens: retinoic acid. Birth Defects Res A 70:344Google Scholar
  3. 3.
    Adams J, Lammer E (1991) Relationship between dysmorphology and neuropsychological functions in children exposed to isotretinoin (in utero). In: Fujii T, Boer GJ (eds) Functional neuroteratology of short term exposure to drugs. Teiko University Press, Tokyo, pp 159–168Google Scholar
  4. 4.
    Azoulay L, Oraichi D, Bérard A (2006) Patterns and utilization of isotretinoin from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 62:667–674. doi: 10.1007/s00228-006-0151-x CrossRefPubMedGoogle Scholar
  5. 5.
    Bérard A, Azoulay L, Koren G et al (2007) Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 63:196–205. doi: 10.1111/j.1365-2125.2006.02837.x CrossRefPubMedGoogle Scholar
  6. 6.
    Dai WS, LaBraico JM, Stern RS (1992) Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 26:599–606. doi: 10.1016/0190-9622(92)70088-W CrossRefPubMedGoogle Scholar
  7. 7.
    David M, Pachaly J, Vetter K (2006) Perinatal outcome in Berlin (Germany) among immigrants from Turkey. Arch Gynecol Obstet 274:271–278. doi: 10.1007/s00404-006-0182-7 CrossRefPubMedGoogle Scholar
  8. 8.
    Garcia-Bournissen F, Tsur L, Goldstein LH, Staroselsky A, Avner M, Asrar F, Berkovitch M, Straface G, Koren G, De Santis M (2008) Fetal exposure to isotretinoin—an international problem. Reprod Toxicol 25:124–128. doi: 10.1016/j.reprotox.2007.10.005 CrossRefPubMedGoogle Scholar
  9. 9.
    Holmes LB (1999) Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 64:79–82Google Scholar
  10. 10.
    Honein MA, Paulozzi LJ, Erickson JD (2001) Continued occurence of accutane exposed pregnancies. Teratology 64:142–147. doi: 10.1002/tera.1057 CrossRefPubMedGoogle Scholar
  11. 11.
    Johnson KA, Weber PA, Jones KL et al (2001) Selection bias in teratology information service pregnancy outcome studies. Teratology 64:79–82. doi: 10.1002/tera.1048 CrossRefPubMedGoogle Scholar
  12. 12.
    Lammer EJ, Chen DT, Hoar RM et al (1985) Retinoic acid embryopathy. N Engl J Med 313:837–841PubMedGoogle Scholar
  13. 13.
    Lammer EJ, Hayes AM, Schunior A et al (1988) Unusually high risk for adverse outcomes of pregnancy following fetal isotretinoin exposure. Am J Hum Genet 43:A 58Google Scholar
  14. 14.
    Martinez-Frias ML, Rodriguez-Pinilla E (1999) The problems of using data from teratology information services (TIS) to identify putative teratogens. Teratology 60:54–55. doi: 10.1002/(SICI)1096-9926(199908)60:2<54::AID-TERA3>3.0.CO;2-3 CrossRefPubMedGoogle Scholar
  15. 15.
    Merks JHM, van Karnebeek CDM, Caron HN, Hennekam RCM (2003) Phenotypic abnormalities: terminology and classification. Am J Med Genet 123:211A–230A. doi: 10.1002/ajmg.a.20249 CrossRefGoogle Scholar
  16. 16.
    Moerike S, Pantzar JT, De Sa D (2002) Temporal bone pathology in fetuses exposed to isotretinoin. Pediatr Dev Pathol 5:405–409. doi: 10.1007/s10024-001-0258-0 CrossRefPubMedGoogle Scholar
  17. 17.
    Moskop JC, Smith ML, De Ville K (1997) Ethical aspects of teratogenic medications: the case of isotretinoin. J Clin Ethics 8:264–278PubMedGoogle Scholar
  18. 18.
    Nulman I, Berkovitch M, Klein J et al (1998) Steady-state pharmacokinetics of isotretinoin and ist 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 38:926–930PubMedGoogle Scholar
  19. 19.
    Ornoy A, Mastroiacovo P (2000) More on data from teratogen information systems (TIS). Teratology 61:327–328. doi: 10.1002/(SICI)1096-9926(200005)61:5<327::AID-TERA2>3.0.CO;2-H CrossRefPubMedGoogle Scholar
  20. 20.
    Raatikainen K, Heiskanen N, Heinonen S (2007) Under-attending free antenatal care is associated with adverse pregnancy outcomes. BMC Public Health 7:268. doi: 10.1186/1471-2458-7-268 CrossRefPubMedGoogle Scholar
  21. 21.
    Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA (2003) Guidelines for case classification for the national birth defects prevention study. Birth Defects Res A 67:193–201. doi: 10.1002/bdra.10012 CrossRefGoogle Scholar
  22. 22.
    Robertson J, Polifka JE, Avner M et al (2005) A survey of pregnant women using isotretinoin. Birth Def Res A 73:881–887. doi: 10.1002/bdra.20197 CrossRefGoogle Scholar
  23. 23.
    Rosa FW (1983) Teratogenicity of isotretinoin. Lancet 2:513. doi: 10.1016/S0140-6736(83)90538-X CrossRefPubMedGoogle Scholar
  24. 24.
    Schaefer C, Arnoy A, Clementi M, Meister R, Weber-Schoendorfer C (2008) Using observational cohort data for studying drug effects on pregnancy outcome—methodological considerations. Reprod Toxicol 26:36–41. doi: 10.1016/j.reprotox.2008.05.064 CrossRefPubMedGoogle Scholar
  25. 25.
    Teratology Society (1991) Recommendations for isotretinoin use in women of child-bearing potential. Teratology 44:1–6. doi: 10.1002/tera.1420440102 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Christof Schaefer
    • 1
    Email author
  • Reinhard Meister
    • 2
  • Corinna Weber-Schoendorfer
    • 1
  1. 1.Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie (BBGes)Berlin Institute for Clinical Teratology and Drug Risk Assessment in PregnancyBerlinGermany
  2. 2.Department of MathematicsBeuth Hochschule für Technik Berlin (University of Applied Sciences)BerlinGermany

Personalised recommendations